Study of Individualized Blood Pressure Management to Protect Brain After Cardiac Arrest Using Cerebral Blood Flow Monitoring

What this Trial Is About

Researchers are evaluating an individualized blood pressure strategy that targets cerebral blood flow after out-of-hospital cardiac arrest OHCA. This approach is compared with standard care to see if it reduces brain injury, measured by changes in neuron-specific enolase, a brain injury biomarker. The study is a proof of concept conducted at a single center and aims to test if personalized blood pressure management improves brain protection after cardiac arrest. The study involves a treatment where blood pressure is carefully adjusted to an individualized target mean arterial pressure during the first 72 hours after return of spontaneous circulation ROSC. This target is determined using brain monitoring software that analyzes data from transcranial Doppler ultrasound and near-infrared spectroscopy, with assessments at admission and at 12, 24, and 48 hours post-ROSC. The intervention group receives this personalized blood pressure management strategy. Participants will be monitored for brain injury using neuron-specific enolase levels at 72 hours post-ROSC as the primary outcome. Secondary outcomes include measurements of heart and kidney injury biomarkers within 72 hours, as well as neurological, physical, cognitive, psychological, and quality of life assessments up to about 12 months after OHCA. The study involves close monitoring and follow-up to evaluate the effects of the intervention over time.

NEUROprotection Via optimizINg Cerebral Blood Flow afTer cArdiaC arresT (NEURO-INTACT) Study